Nycomed - nycomed.com - Nycomed News RSS feed
General Information:
Latest News:
Takeda Receives Marketing Authorization from China’s CFDA for New Type 2 Diabetes Therapy NESINA (alogliptin) 31 Jul 2013 | 12:59 pm
Osaka, Japan, and Shanghai, China, July 31, 2013– Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) and its wholly-owned subsidiary, Takeda (China) Holdings Co., Ltd. today announced that th...
Takeda and Sanofi Sign Co-promotion Agreement to Expand Reach of Diabetes Treatment Alogliptin in China 22 Apr 2013 | 01:08 pm
• Alogliptin is a DPP-4 inhibitor that is designed to slow the inactivation of incretin hormones GLP-1 and GIP• Agreement is part of Takeda’s strategy to complement capabilities through partnerships• ...
Takeda Launches New Subsidiary in Ecuador 21 Mar 2013 | 01:20 pm
Demonstrates Takeda’s long-term commitment to the Latin American market Zurich, Switzerland, March 21, 2013 --- Takeda Pharmaceuticals International GmbH (“Takeda”), today announced further expansion ...
NPS Pharmaceuticals and Takeda Revise Agreements and NPS Re-Gains Full Worldwide Rights to Teduglutide and Recombinant Human Parathyroid Hormone 1-84 19 Mar 2013 | 01:33 pm
BEDMINSTER, New Jersey and Osaka, Japan – March 19, 2013 – NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) announced today that NPS has re-gain...
Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the Euro... 7 Mar 2013 | 11:00 am
Osaka, Japan – March 7, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”) today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EM...
Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazo... 26 Jan 2013 | 11:00 am
Deerfield, Ill., January 25, 2013, and Osaka, Japan, January 26, 2013 – Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announ...
Takeda Establishes New Trading Company and Reinforces Business Structure in China 22 Jan 2013 | 11:00 am
Osaka, Japan, January 22, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”) today announced the launch of a new trading company in China, Takeda (China) International Trading Co., Ltd. (“TCIT”),...
Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceutical 18 Dec 2012 | 11:00 am
Deerfield, Ill., Dec. 17, 2012 and Osaka, Japan, Dec. 18, 2012 – Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda’s wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., In...
Takeda and Millennium Announce European Conditional Marketing Authorisation for ADCETRIS® (Brentuximab Vedotin) 31 Oct 2012 | 10:00 am
Osaka, Japan, and Cambridge, Mass., October 31, 2012 – Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”) and Millennium: The Takeda Oncology Company, today announced that the European Commiss...
Takeda Completes its Russian Pharmaceutical Manufacturing Facility 12 Sep 2012 | 10:00 am
• State-of-the-art facility in Yaroslavl demonstrates Takeda’s long-term commitment to the Russian market • Plant expected to be fully operational in 2014, supplying high quality tablet and sterile li...
